Cognito Therapeutics Archives - FinSMEs

FinSMEs The Website About Venture Capital News . USA. UK. Germany. France. Canada. India. Italy. Search. Home Tags Cognito Therapeutics. Tag: Cognito Therapeutics. USA. Cognito …

CouponFollow Extension

$73
OFF

IAG Capital Archives - FinSMEs

1 week from now

Cognito Therapeutics Raises $73M in Series B Funding. Published on March 22, 2023 March 22, ... FinSMEs is owned by FinSMEs Ltd - 86 - 90 Paul Street - London, UK - EC2A 4NE ...

finsmes.com

$35
OFF

Cognito Nets $35 Million To Advance Alzheimer's DTx Trial

1 week from now

Jan 29, 2024 · Cognito Therapeutics has raised $35 million to advance its digital therapeutic (DTx) for Alzheimer's disease, the company's CEO Brent Vaughan told FirstWord HealthTech …

firstwordhealthtech.com

$73
OFF

Cognito Collects $73M For Light-and-sound Alzheimer's Therapy

1 week from now

Mar 22, 2023 · The series B round adds $73 million to Cognito’s coffers, the startup announced Wednesday. It’ll go toward the ongoing pivotal study of the noninvasive headset, which relies …

fiercebiotech.com

$20000
OFF

Newark Archives Project « Newark History Society – Newark, New …

1 week from now

The Newark History Society has received new grants to fund ongoing work on the Newark Archives Project database. The New Jersey Historical Commission awarded a $20,000 grant …

newarkhistorysociety.org

FAQs about Cognito Therapeutics Archives - FinSMEs Coupon?

Does Cognito therapeutics have a series B financing?

CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. ...

Who is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. ...

What is Cognito therapeutic's neurostimulation device?

Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA). ...

Is Cognito a non-invasive neuromodulation device?

Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. ...

Can a Cognito Sham device slow Alzheimer's?

Cognito thinks its device could slow the cognitive decline that comes with the disease by strengthening and synchronizing these connections. The company’s study included 74 participants with mild to moderate Alzheimer’s who received either the Cognito stimulation or a sham device that acted as a placebo. ...

Can a non-drug neuromodulation intervention help treat Alzheimer's & Cognito?

“A non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimer’s and Cognito is well-positioned to be a leader in this new paradigm,” said Helen Liang, Founder & Managing Partner, FoundersX Ventures. ...